Nektar Therapeutics Files Q1 2025 10-Q
Ticker: NKTR · Form: 10-Q · Filed: May 9, 2025 · CIK: 906709
Sentiment: neutral
Topics: 10-Q, biotech, collaboration, financials
Related Tickers: BMY
TL;DR
Nektar's Q1 2025 10-Q is in. Check out the Bristol Myers Squibb deal updates.
AI Summary
Nektar Therapeutics filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key agreements mentioned include the Bristol Myers Squibb Collaboration Agreement from February 12, 2024, and a Purchase and Sale Agreement from December 16, 2020.
Why It Matters
This filing provides investors with an update on Nektar Therapeutics' financial health and ongoing business activities, including details on significant collaborations.
Risk Assessment
Risk Level: medium — Biotech companies like Nektar Therapeutics are subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End (Financial data pertains to this date.)
- 2025-01-01 — Reporting Period Start (Financial data pertains to this period.)
- 2024-12-31 — Previous Year End (Comparative financial data.)
Key Players & Entities
- NEKTAR THERAPEUTICS (company) — Filer
- Bristol Myers Squibb Collaboration Agreement (company) — Key agreement
- 20250331 (date) — Reporting period end date
- 20250509 (date) — Filing date
- 455 MISSION BAY BOULEVARD SOUTH (address) — Business and mailing address
FAQ
What was the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing was for the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 9, 2025.
What is Nektar Therapeutics' primary business classification?
Nektar Therapeutics is classified under Pharmaceutical Preparations [2834].
What is the business address of Nektar Therapeutics?
The business address is 455 Mission Bay Boulevard South, San Francisco, CA 94158.
What is a significant collaboration agreement mentioned in the filing?
A significant collaboration agreement mentioned is the Bristol Myers Squibb Collaboration Agreement, dated February 12, 2024.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding NEKTAR THERAPEUTICS (NKTR).